GenomiCare Biotechnology has completed US$25 million Series A financing co-launched by Morningside Venture Capital, Apricot Tree Capital and Carebridge Holdings, for which China Renaissance Group provides exclusive financial consulting service.
Xu Qiang, founder, president and CEO of GenomiCare, said the funds will primarily be used to strengthen self-capability building of GenomiCare, provide more precise testing and better full-solution management for Chinese tumour patients; to step up efforts to promote targeted therapy service nationwide, advance strategic collaboration with hospitals; and to combine the most comprehensive genetic variation data with patients’ pathological data and lifelong follow-up visits, to create a complete “genetic + clinical” precise medical database.
Founded in 2015, GenomiCare is headquartered in Zhangjiang Hi-tech Park, Shanghai. It respectively owns an independent lab in Shanghai Zhangjiang Yaogu and a medical lab in Qidong, Jiangsu. Meanwhile, it has co-established precision medical lab with East China Institute of Life Sciences Industry of Peking University. GenomiCare management team consists of veteran management staff from Peking University, Harvard University, University of California, CAS and Fudan University. Since its establishment, GenomiCare has been dedicated to provide personalised and targeted clinical solutions and global resource matching service. So far, GenomiCare has provided precise medical services for nearly 3,500 patients in China.
